Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.

@article{Lee2018TenofovirDF,
  title={Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.},
  author={Sae Hwan Lee and Gab Jin Cheon and Hong Soo Kim and Sang Gyune Kim and Young Seok Kim and Soung Won Jeong and Jae Young Jang and Boo Sung Kim and Baek Gyu Jun and Young Don Kim and Dae Won Jun and Joo Hyun Sohn and Tae Yeob Kim and Byung Seok Lee},
  journal={Antiviral therapy},
  year={2018},
  volume={23 3},
  pages={
          219-227
        }
}
BACKGROUND A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therapy in patients with suboptimal responses… CONTINUE READING